Methylene Blue Against Falciparum Malaria in Burkina Faso
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
Safety of artesunate-amodiaquine combined with methylene blue or primaquine for falciparum
malaria treatment in African children: A randomised controlled trial
Elimination has become the goal of malaria programmes in an increasing number of endemic
countries and regions. As resistance against artemisinin compounds has recently started to
emerge in South-East Asia, there is a clear need to develop alternative malaria drug
combinations. Adding another anti-malarial with a short half-life such as methylene blue to
standard ACT (artemisinin-based combination therapy) could be a strategy to prevent
artemisinin resistance development. Moreover, adding a gametocytocidal drug to ACT reduces
the probability of transmission of P. falciparum parasites including drug-resistant
parasites.
Objectives: The primary objective of this trial is to investigate the safety of artesunate
(AS) - amodiaquine (AQ) - methylene blue (MB) compared to AS - AQ - primaquine (PQ) in young
children with uncomplicated falciparum malaria in Burkina Faso.
Phase:
Phase 2
Details
Lead Sponsor:
Heidelberg University
Collaborator:
Centre de Recherche en Sante de Nouna, Burkina Faso
Treatments:
Amodiaquine Artesunate Methylene Blue Phenothiazine Primaquine